Neutrophil Gelatinase-associated Lipocalin VS Vascular Calcification in Maintenance Hemodialysis Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2025

Conditions
Chronic Kidney Disease-Mineral and Bone Disorder
Interventions
DRUG

palicalcitol

This study does not interfere with the clinical medication of the researchers, and the usage and dosage of the drugs will be recorded according to the actual use. The recommended starting dose of palicalcitol may be based on body weight, baseline iPTH, or combined with prior medication. Dose adjustment should be determined according to pre-dialysis iPTH, Ca and P. iPTH levels should be maintained at 150-300pg/ml, while Ca and P levels should be closely monitored. If hypercalcemia occurs, the dose should be reduced or medication should be discontinued until these parameters return to normal; Subsequently, the dose of palicalcitol should be restarted at a lower dose. If PTH levels decrease as a result of treatment, the dose of medication may need to be reduced accordingly. The dose adjustment interval is 2-4 weeks, and the dose can be adjusted immediately for safety reasons.

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan

All Listed Sponsors
lead

Xiaoyan Jia

OTHER